Discover investment opportunities in List Of Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Pharma Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in List Of Pharma Stocks using our Smart AI Filter.
10 stocks found for "List Of Pharma Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.45 | ±20.5% | 12.7 | 3.02% | |||
0.33 | ±27.9% | 8.6 | 4.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.37 | ±19.7% | 14.7 | 3.18% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.35 | ±28.9% | 6.7 | 5.29% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What attracts investors to Pfizer (PFE) stock?
A: Pfizer is known for its strong pharmaceutical pipeline, significant role in COVID-19 vaccine development, and consistent dividend payments. These factors appeal to growth and income investors. Additionally, Pfizer's global presence can offer some diversification benefits.
Q: Is Merck (MRK) considered a good investment for income-focused investors?
A: Merck has a history of providing stable dividends, attracting income-focused investors. Investors may view its robust portfolio of cancer and vaccine products as an income stability factor, though they should assess dividend sustainability individually.
Q: How does Johnson & Johnson (JNJ) manage risk through its diversified business model?
A: Johnson & Johnson's diversified product lines across pharmaceuticals, medical devices, and consumer health products help mitigate sector-specific risks. This diversity may reduce volatility and provide some stability during different economic cycles.
Q: What are the potential growth drivers for Eli Lilly (LLY) in the coming years?
A: Eli Lilly's pipeline of innovative drugs, particularly in diabetes and oncology, represents strong growth potential. Some investors consider regulatory approvals and successful commercialization of newer products as key growth drivers.
Q: How does Bristol-Myers Squibb (BMY) enhance its competitive position through acquisitions?
A: Bristol-Myers Squibb frequently utilizes strategic acquisitions to strengthen its drug portfolio and enhance competitive positioning, as seen with the Celgene acquisition. These are considered pivotal in expanding its cancer and immunology drug lines.
Q: How does AbbVie (ABBV) balance high dividend yield with debt levels?
A: AbbVie's high dividend yield appeals to income investors, with cash flow supported by blockbuster drugs like Humira. Investors must weigh this against its elevated debt, a product of acquisitions like Allergan, affecting overall financial health.
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments by the pharmaceutical industry as President Donald Trump threatens to clamp down on the industry with tariffs on pharmaceuticals imported into the country.
Read morePresident Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more